STOCK TITAN

Alpine Immune Sciences Inc - ALPN STOCK NEWS

Welcome to our dedicated news page for Alpine Immune Sciences (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpine Immune Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpine Immune Sciences's position in the market.

Rhea-AI Summary
Alpine Immune Sciences to participate in healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences
-
Rhea-AI Summary
Alpine Immune Sciences to present new preclinical data on povetacicept at ANA Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences clinical trial
-
Rhea-AI Summary
Alpine Immune Sciences successfully initiates second dose cohort in autoimmune glomerulonephritis study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
clinical trial
Rhea-AI Summary
Alpine Immune Sciences appoints M. Christina Yi as Chief Technology Officer, with her expertise and leadership expected to be important for the company's pipeline development. Wayne Gombotz will retire in August. Ms. Yi has been granted an option to purchase 185,000 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
management
-
Rhea-AI Summary
Alpine Immune Sciences, Inc. reported financial results for Q2 2023, with cash and investments totaling $239.6 million. The company initiated patient enrollment in the RUBY-4 study of povetacicept in autoimmune cytopenias and continues to enroll patients in the RUBY-3 study of povetacicept in autoimmune glomerulonephritis. Preliminary data from RUBY-3 will be presented at the American Society of Nephrology Meeting in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.25%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
conferences clinical trial
Alpine Immune Sciences Inc

Nasdaq:ALPN

ALPN Rankings

ALPN Stock Data

2.53B
44.93M
4.63%
91.2%
6.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About ALPN

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.